OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Daniel Some, PhD, is director of marketing and principal scientist, at Wyatt Technology Corporation, 6300 Hollister Ave, Santa Barbara, CA 93117-3253.
This article introduces the technology that powers automated HT–DLS and explores its practical applications in enhancing formulation stability investigations.
BioPharm International
eBooks Volume 28, Issue 14
Assessing a drug candidate’s suitability during preformulation is essential to minimize the risk of costly downstream failure. Stability is a defining feature of biotherapeutic performance; measuring formulation stability during early-phase screening allows developers to make robust predictions of suitability for further development. Read this article and other articles in
BioPharm International
's 2015
eBook.
Related Content:
Formulation | Analytical Methods | Biopharmaceutical Analysis | Drug Delivery | Formulation and Drug Delivery, Other | Development